ADAURA trial shows sustained overall survival benefit of adjuvant osimertinib in resected EGFR‑mutated NSCLC

An eight‑year landmark update from the Phase III ADAURA trial was presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer, confirming that adjuvant osimertinib continues to deliver a long‑term overall survival advantage for patients with completely resected, EGFR‑mutated stage IB–IIIA non‑small cell lung cancer (NSCLC). The analysis, which represents the longest follow‑up to date for the study, showed that patients receiving osimertinib after surgery experienced significantly higher survival rates compared with those who did not receive the targeted therapy, reinforcing the drug’s role in the postoperative management of this molecularly defined subgroup.

The findings underscore the durability of osimertinib’s benefit in the adjuvant setting and provide robust evidence for its continued use as a standard of care in resected EGFR‑mutated NSCLC. Researchers highlighted that the survival advantage persisted across all disease stages included in the trial, with no new safety concerns emerging over the extended observation period. The results are expected to influence clinical guidelines and support ongoing efforts to improve long‑term outcomes for patients with early‑stage, EGFR‑driven lung cancer.